CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal) Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Dasatinib, administered once daily, as compared with imatinib, administered once daily, induced significantly higher and faster rates of complete cytogenetic response and major molecular response. [N Engl J Med] Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia Nilotinib at a dose of either 300 mg or 400 mg twice daily was superior to imatinib in patients with newly diagnosed chronic-phase Philadelphia chromosome-positive chronic myeloid leukemia. [N Engl J Med] Radioimmunotherapy with Yttrium-90-Ibritumomab Tiuxetan as Part of a Reduced Intensity Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Advanced Non-Hodgkin Lymphoma: Results of a Phase II Study Allogeneic hematopoietic cell transplantation using reduced intensity conditioning offers a potential curative therapy to patients with advanced non-Hodgkin lymphoma. [Blood] The Human Stem Cell Hierarchy Is Defined by a Functional Dependence on Mcl-1 for Self-Renewal Capacity Researchers report a role for the Bcl-2 family member myeloid cell leukemia -1 (Mcl-1) as an indispensable regulator of self-renewal in human stem cells, and show that a functional dependence on Mcl-1 defines the human stem cell hierarchy. [Blood] Interleukin-7 Permits Th1/Tc1 Maturation and Promotes Ex Vivo Expansion of Cord Blood T Cells: A Critical Step toward Adoptive Immunotherapy after Cord Blood Transplantation Findings offer a major step in fulfilling critical numerical and biological requirements to quickly generate a donor leukocyte infusion product ex vivo using a negligible fraction of a cord blood graft that provides a flexible adoptive immunotherapy platform for both children and adults. [Cancer Res] Umbilical Cord Mesenchymal Stem Cell Transplantation in Severe and Refractory Systemic Lupus Erythematosus Umbilical cord derived mesenchymal stem cell transplantation resulted in amelioration of disease activity, serological changes, and stabilization of proinflammatory cytokines. [Arthritis Rheum] Tumor Necrosis Factor-Induced Neutrophil Adhesion Occurs Via Sphingosine Kinase-1-Dependent Activation of Endothelial Alpha5Beta1 Integrin Researchers demonstrate that tumor necrosis factor alpha activates the integrin alpha5beta1 without altering total expression levels of beta1 integrin on human umbilical vein endothelial cells. [Am J Pathol] Non-Senescent Hsp27-Upregulated MSCs Implantation Promote Neuroplasticity in Stroke Model In this study, researchers demonstrated that implantation of human umbilical cord mesenchymal stem cells (MSCs) cultured in human umbilical cord serum significantly enhanced neuroplasticity and angiogenesis in stroke and ischemic limb models. [Cell Transplant] World Marrow Donor Association Framework for the Implementation of HLA Matching Programs in Hematopoietic Stem Cell Donor Registries and Cord Blood Banks This study defines a comprehensive framework for HLA matching programs, which use intricate algorithms to rapidly select potential donors for a patient from a database and to present these donors in a prioritized list. [Bone Marrow Transplant] Long-Term Results of High-Dose Chemotherapy with Autologous Bone Marrow or Peripheral Stem Cell Transplant as First Salvage Treatment for Relapsed or Refractory Hodgkin Lymphoma: A Single Institution Experience Long-term results confirm that high-dose chemotherapy and autologous stem cell or bone marrow transplant was feasible, safe, and very effective. [Leuk Lymphoma]
|
INDUSTRY NEWS Tecan Announces OEM Agreement with Global Diagnostics Company The Tecan Group announced a global OEM agreement with the diagnostics business of Novartis for the supply of a new high-throughput instrument designed to provide blood banks with a flexible, single-platform pooling and archiving solution. [Tecan Trading AG Press Release] Cleveland Cord Blood Center Participates in Ohio Third Frontier Wright Projects Program Award The Cleveland Cord Blood Center received notice from the Ohio Third Frontier Wright Projects Program that it has been designated in a 3-year $2.1 million award to collaborate with Case Western Reserve University and Cleveland Clinic Foundation on the project, “Development of a Quantitative Analysis System for Stem Cells.” [PR Newswire] ISSCR Launches Web Site Providing Information on Stem Cell Treatments The International Society for Stem Cell Research (ISSCR) announced that it has launched “A Closer Look at Stem Cell Treatments” (www.closerlookatstemcells.org), a web site to arm patients, their families and doctors with information they need to make decisions about stem cell treatments. [International Society for Stem Cell Research Press Release] BioSante Announces FDA Orphan Drug Designation for GVAX Chronic Myeloid Leukemia Cancer Vaccine BioSante Pharmaceuticals, Inc. announced the receipt of Orphan Drug designation for GVAX CML Vaccine in the treatment of chronic myeloid leukemia from the FDA’s Office of Orphan Products Development. [BioSante Pharmaceuticals, Inc. Press Release] ARIAD Presents Updated Clinical Data on Its Investigational Pan-BCR-ABL Inhibitor, AP24534, in Drug-Resistant Chronic Myeloid Leukemia ARIAD Pharmaceuticals, Inc. announced updated clinical data from an ongoing Phase I study of its investigational pan-BCR-ABL inhibitor, AP24534, in patients with resistant and refractory chronic myeloid leukemia. [ARIAD Pharmaceuticals, Inc. Press Release] Data from Study of Revlimid® in Untreated Patients with Chronic Lymphocytic Leukemia Presented at ASCO Celgene International Sàrl announced that researchers presented data from an investigator-initiated Phase II study of lenalidomide (Revlimid®) in untreated patients with chronic lymphocytic leukemia at the annual meeting of the American Society of Clinical Oncology (ASCO). [Celgene International Sàrl Press Release] Soligenix Announces Grant of European Patent for the Treatment of GVHD and Leukemia with Oral Beclomethasone Dipropionate Soligenix, Inc. announced that the European Patent Office granted patent EP 1830857 “Method of Treatment of Graft-versus-Host Disease and Leukemia with Beclomethasone Diproprionate and Prednisone.” [Soligenix, Inc. Press Release] Cord Blood Service All Set for Formal Launch Marking a major step in Qatar’s bid to benefit from stem cell therapies, Virgin Health Bank Qatar Science & Technology Park (VHB QSTP) is to officially launch its cord blood banking services at the Women’s Hospital of Hamad Medical Corporation. [The Gulf Times]
|
POLICY NEWS Stroke Prevention Study in Children with Sickle Cell Anemia, Iron Overload Stopped Early The National Heart, Lung, and Blood Institute has stopped a clinical trial evaluating a new approach to reduce the risk of recurrent stroke in children with sickle cell anemia and iron overload because of evidence that the new treatment was unlikely to prove better than the existing treatment. [National Heart, Lung, and Blood Institute Press Release] FDA Announces Collaboration with Drugs.com The U.S. Food and Drug Administration announced that it will collaborate with the web site Drugs.com to expand access to the FDA’s consumer health information. [Food and Drug Administration, United States] Administrative Supplements to Increase Public Awareness of Pediatric Cancers and Available Treatments and Research (NOT-CA-10-026) [National Institutes of Health, United States] 2010 Biological License Application Approvals [Food and Drug Administration, United States] 2010 Biological Device Application Approvals [Food and Drug Administration, United States] Emerging Infectious Diseases: Evaluation to Implementation for Transfusion and Transplantation Safety Public Workshop (Update) [Food and Drug Administration, United States]
|
EVENTS 8th International Conference on Cell and Stem Cell Engineering (ICCE2010) June 11-12, 2010 Dublin, Ireland International Society for Stem Cell Research (ISSCR) 8th Annual Meeting June 16-19, 2010 San Francisco, United States Select Biosciences 3rd Annual Stem Cells Europe Conference August 24-25, 2010 Edinburgh, Scotland Select Biosciences World Biobanking Summit August 24-25, 2010 Edinburgh, Scotland Select Biosciences Inaugural Cellular Therapy Summit August 24-25, 2010 Edinburgh, Scotland International Society for Cellular Therapy – Europe 2nd Regional Meeting September 11-14, 2010 Belgirate, Italy Stem Cells USA & Regenerative Medicine Congress 2010 September 13-15, 2010 Philadelphia, United States Tissue Engineering & Regenerative Medicine International Society (TERMIS) – Asia Pacific 2010 September 15-17, 2010 Sydney, Australia International Society for Hematology and Stem Cells (ISEH) 2010 Meeting September 15-18, 2010 Melbourne, Australia AABB (formerly known as the American Association of Blood Banks) Annual Meeting & Cellular Therapy and Transfusion Medicine Expo (CTTXPO) 2010 October 9-12, 2010 Baltimore, United States Institute for Genomic Medicine Inaugural Symposium October 11-12, 2010 San Diego, United States Fraunhofer Life Science Symposium Leipzig 2010 October 29-30, 2010 Leipzig, Germany Select Biosciences 2nd International Forum on Stem Cells (2010 IFSC) November 12-13, 2010 Tianjin, China 52nd American Society of Hematology (ASH) Annual Meeting and Exposition December 4-7, 2010 Orlando, United States Select Biosciences 5th Annual Stem Cells World Congress January 24-25, 2011 San Diego, United States Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.
JOB OPPORTUNITIES Senior Scientist – Magnetic Cell Separation (STEMCELL Technologies) Business Development Manager Europe – Cell Therapy Products (Pall Corporation)
Manager/Sr. Manager, Therapeutic Cell Solutions, Process Development (Lonza) Sr. Product Support and Training Specialist (CardianBCT) Recruit Top Talent Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cord Blood News. Visit here to post your career opportunities. Have we missed an important article or publication in Cord Blood News? Click here to submit!
Comments or Suggestions? Email info@connexoncreative.com with your feedback. |
|
|